Drug Profile
Silatecan - Vivacitas Oncology
Alternative Names: (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin; AR-67; DB-67Latest Information Update: 14 May 2021
Price :
$50
*
At a glance
- Originator University of Pittsburgh
- Developer Arno Therapeutics; TaiGen Biotechnology; TTY Biopharm
- Class Antineoplastics; Camptothecins; Organosilicon compounds; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Glioblastoma
- Phase I Solid tumours
- Discontinued Myelodysplastic syndromes
Most Recent Events
- 14 May 2021 Efficacy and adverse events data from a phase I trial in Solid tumours (Second-line therapy or greater, Metastatic disease) released by Vivacitas Oncology (Vivacitas Oncology pipeline, May 2021)
- 14 May 2021 Vivacitas Oncology plans a phase III trial in Glioblastoma(Vivacitas Oncology pipeline, May 2021)
- 10 May 2021 Silatecan is still in phase-I clinical trials in Solid tumours (Second-line therapy or greater, Metastatic disease) in USA (IV) (Vivacitas Oncology pipeline, May 2021)